Key facts
- This page summarizes Gregory D. Davis's Form 4 filing for SANGAMO THERAPEUTICS, INC (SGMO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 26 Jan 2026, 16:08.
Gregory D. Davis - 22 Jan 2026 Form 4 Insider Report for SANGAMO THERAPEUTICS, INC (SGMO)
- Reporting relationship
- Head of Research & Technology
- Issuer ticker
- SGMO
- Reported as of
- 22 Jan 2026
- Net transaction value
- -$3,077
- SEC form
- 4
- Accepted by SEC
- 26 Jan 2026, 16:08:45 UTC
- Prior SEC filing
- 26 Nov 2025
- Next SEC filing
- 26 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Scott Willoughby, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gregory D. Davis filed Form 4 for SANGAMO THERAPEUTICS, INC (SGMO) on 26 Jan 2026.
Change
- Previous filing in this sequence was filed on 26 Nov 2025.
- Current net transaction value: -$3,077.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002041855
Primary reporting owner
Davis Gregory D
- Relationship
- Head of Research & Technology
- Address
- C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND
- Signature
- /s/ Scott Willoughby, Attorney-in-Fact
- Signature date
- 26 Jan 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SGMO
transaction
Common Stock
Tax liability
- Transaction value
- $3,077
- Shares
- -7,721
- Change %
- -3.9%
- Price
- $0.3985
- Shares after
- 191,062
- Date
- 22 Jan 2026
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on January 22, 2026, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026 of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
Footnote F2
Includes: (a) 11,029 shares from the January 22, 2026 vesting installment of the Reporting Person's January 22, 2024 RSU grant, (b) 2,022 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest in successive equal quarterly installments through February 24, 2026 and (c) 49,726 shares subject to Reporting Person's February 25, 2025 RSU grant that will vest as to one-quarter (1/4) of the shares on February 25, 2026, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Footnote F3
Includes 5,000 shares acquired on May 30, 2025 under the Issuer's 2020 Employee Stock Purchase Plan.
Footnote F4
The Reporting Person previously transferred 8 shares of the Issuer's common stock to his ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.